Turn Therapeutics reported cash from operations of -$0.97M and free cash flow of -$0.97M for the quarter ended Jun 2026, down 93.5% year over year. This cash flow statement covers 8 quarters of results from Sep 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | -0.67M | -0.32M | -0.57M | -1.36M | -1.91M | -2.18M | -1.74M | -1.87M |
| Share-based Compensation | 0.04M | 0.08M | 0.05M | 3.00M | 0.69M | 1.94M | 3.35M | |
| Asset Writedowns and Impairment | 0.48M | 0.64M | ||||||
| Cash from Operations | -0.43M | -0.30M | -0.50M | -0.59M | -1.21M | -1.63M | -0.97M | |
| Depreciation, Depletion & Amortization | ||||||||
| Amortizatization of Intangibles | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | |||
| Change in Working Capital | ||||||||
| Change in Accured Expenses | 0.05M | -0.02M | 0.37M | 1.25M | 0.66M | -0.61M | 0.29M | |
| Other Working Capital Changes | 0.22M | 0.29M | -0.31M | -0.02M | -0.07M | 0.12M | -0.10M | |
| Investing Activities | ||||||||
| Cash from Investing Activities | -0.01M | -0.09M | -0.03M | -0.01M | -0.01M | |||
| Financing Activities | ||||||||
| Change in Capital Stock | ||||||||
| Net Shares Issued and Repurchased | 0.30M | 0.30M | ||||||
| Net Equity Issued and Repurchased | 75.00M | 1.00M | 2.15M | 0.59M | 3.18M | |||
| Misc. | ||||||||
| Cash from Financing Activities | 0.52M | 1.00M | 2.15M | 0.59M | 3.18M | 7.79M | 1.00 | |
| Change in Cash | 0.08M | 0.70M | 1.62M | -0.08M | 1.97M | 6.14M | -0.93M | |
| Free Cash Flow | -0.43M | -0.30M | -0.50M | -0.59M | -1.21M | -1.63M | -0.97M | |
| Net Cash Flow | 0.08M | 0.70M | 1.65M | -0.09M | 1.94M | 6.14M | -0.97M |